Fibrin Specific Neutra™ Antibody Products

Are you struggling with prolonged timelines in thrombosis research, inconsistent fibrin-binding assays, or insufficient tools for neutralizing pathological fibrin activity? Creative Biolabs' fibrin specific Neutra™ antibody products empower your research through advanced epitope-specific engineering and rigorous functional validation, enabling rapid identification of fibrin-driven pathologies and development of high-efficacy therapies.

Introduction to Fibrin

Fibrin, an insoluble polymeric protein, serves as the primary structural component of blood clots. Generated via thrombin-mediated cleavage of fibrinogen, fibrin monomers polymerize into a fibrous mesh during hemostasis to stabilize platelet plugs. Beyond its physiological role in wound healing, dysregulated fibrin formation underpins thrombotic diseases such as deep vein thrombosis, pulmonary embolism, and stroke.

• Structural Complexity

Fibrin assembly involves sequential molecular interactions:

- Monomer polymerization: Cleaved fibrinogen releases fibrinopeptides A and B, exposing binding sites that facilitate staggered end-to-middle domain linkages between monomers.

- Branching networks: Lateral aggregation of protofibrils forms a porous, branched scaffold that entraps platelets and red blood cells.

- Crosslinking stabilization: Factor XIIIa catalyzes covalent γ-chain and α-chain crosslinks, enhancing clot mechanical stability and resistance to fibrinolysis.

• Pathological Signaling Pathways

Fibrin directly modulates cellular and immune responses in thrombotic microenvironments:

- Inflammation: Fibrin binds integrins (e.g., αMβ2) on leukocytes, activating NF-κB and promoting cytokine release.

- Angiogenesis: Degradation fragments (e.g., fibrin E-fragment) stimulate endothelial cell proliferation via VEGF receptor crosstalk.

- Fibrinolysis resistance: Fibrin binds plasminogen activators (tPA, uPA) and their inhibitors (PAI-1), regulating clot dissolution dynamics.

Fig.1 Role of fibrin in fibrinolysis.¹

• Associated Pathologies

Abnormal fibrin deposition drives thrombotic events in cardiovascular diseases, cancer-associated coagulopathies, and autoimmune disorders like antiphospholipid syndrome. Elevated fibrin levels correlate with poor prognosis in sepsis due to microvascular occlusion and organ dysfunction.

Applications of Anti-Fibrin Neutralizing Antibodies

• Diagnostic Assay Development

Anti-fibrin antibodies enable quantitative detection of fibrin degradation products (D-dimers) in plasma, aiding early diagnosis of disseminated intravascular coagulation (DIC) and monitoring thrombolytic therapy efficacy.

• Target Validation in Preclinical Models

Utilize neutralizing antibodies to dissect fibrin's role in disease progression. For example, antibody-mediated fibrin suppression reduces metastatic niche formation in murine cancer models by inhibiting tumor cell adhesion to clot matrices.

• Therapeutic Candidate Screening

Incorporate anti-fibrin antibodies into high-throughput platforms to identify small molecules or biologics that synergistically enhance fibrinolytic activity. This approach accelerates lead optimization for novel antithrombotics.

• Personalized Thrombosis Management

Antibody-based profiling of patient fibrin structure (e.g., clot density, fiber diameter) predicts responses to anticoagulants, guiding tailored regimens for individuals at high risk of recurrent thrombosis.

Our Anti-Fibrin Antibodies

Creative Biolabs' anti-fibrin antibodies target conformationally sensitive epitopes critical for clot formation and stability:

- Neutralization mechanisms: Antibodies block fibrin polymerization by competitively inhibiting monomer aggregation sites or destabilizing protofibril interactions.

- Functional applications: Validate antibody efficacy in thromboelastography (TEG), turbidity assays, and in vivo thrombosis models.

- Therapeutic potential: Engineered for high affinity (>1 nM) and low immunogenicity, these antibodies support development of safer anticoagulants with reduced bleeding risks.

Creative Biolabs provides fibrin specific Neutra™ antibody products, combining unmatched specificity and reproducibility to advance thrombosis research and therapeutic innovation. Our antibodies are validated across ELISA, immunohistochemistry, and functional clotting assays, ensuring robust data generation. Contact our team today to explore custom solutions for your project.

REFERENCE

1. Hvas, Christine Lodberg, and Julie Brogaard Larsen. "The fibrinolytic system and its measurement: history, current uses and future directions for diagnosis and treatment." International Journal of Molecular Sciences 24.18 (2023): 14179. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms241814179